目的 探究肺康复训练联合药物吸入治疗中重度慢性阻塞性肺疾病(COPD)患者疗效。方法 选取2016年2月-2018年2 月我院收治的中重度COPD患者140例，按照随机抽签法将患者分为观察组与对照组各70例，对照组予以沙美特罗替 卡松雾化吸入，观察组采用肺康复训练联合沙美特罗替卡松雾化吸入治疗，观察两组患者治疗前后第一秒用力呼气 容积与用力肺活量比值(FEV1/FVC)、1秒钟用力呼气容积占预测值百分比(FEV1%Pre)、最大自主通气量(MVV)、6min 步行试验(6MWT)并记录及COPD评估测试(CAT)变化。结果 治疗后两组患者FEV1/FVC、FEV1%Pre及MVV均明显高于治疗 前(P＜0.05)，且观察组显著高于对照组(P＜0.05)；治疗后观察组6MWT显著高于对照组(P＜0.05)，CAT评分明显低 于对照组(P＜0.05)。结论 肺康复训练联合沙美特罗替卡松吸入治疗中重度COPD可通过有效改善肺功能、增强运动 耐力来患者提高生活质量。

Objective To explore the efficacy of pulmonary rehabilitation training combined with drug inhalation in the treatment of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Methods A total of 140 patients with moderate-to-severe COPD admitted to our hospital from February 2016 to February 2018 were selected. According to the random sampling method, the patients were divided into observation group and control group, with 70 cases in each group. Control group was treated with aerosol inhalation of salmeterol and fluticasone propionate, and observation group was given pulmonary rehabilitation training combined with aerosol inhalation of salmeterol and fluticasone propionate. The ratio of forced expiratory volume in 1s and forced vital capacity (FEV1/FVC), percentage of forced expiratory volume in 1s of predicted value(FEV1%Pre), maximum voluntary ventilation (MVV) and 6-min walking test (6MWT) were observed in the two groups before and after treatment, and the COPD assessment test (CAT) was recorded. Results After treatment, the FEV1/FVC, FEV1% Pre and MVV in the two groups were significantly higher than those before treatment (P<0.05), and the indexes in observation group were significantly higher than those in control group (P<0.05). After treatment, the 6MWT in observation group was significantly higher than that in control group (P<0.05), and the CAT score was significantly lower than that in control group (P<0.05). Conclusion Pulmonary rehabilitation training combined with salmeterol and fluticasone propionate inhalation can improve the quality of life by effectively improving pulmonary function and enhancing exercise tolerance in the treatment of moderate-to-severe COPD.